VahatiCor Enrolls First U.S. Patient in Innovative Clinical Study for CMD Treatment

VahatiCor's Groundbreaking Step in CMD Treatment

In a significant development for patients suffering from coronary microvascular dysfunction (CMD), VahatiCor, Inc. has enrolled its first American patient in its SERRA-I clinical study, which assesses the innovative A-FLUX Reducer System. This is a notable milestone in VahatiCor's ongoing commitment to advancing medical technology and improving patient outcomes.

CMD affects millions who experience persistent chest pain and associated symptoms without any obstruction in the major coronary arteries. Affected individuals may struggle with inadequate treatment options, as current therapies in the U.S. fail to directly address this microvascular condition. The A-FLUX Reducer, a self-expanding nitinol implant, aims to ameliorate blood flow in the small cardiac vessels and address the underlying microvascular dysfunction.

A First Step in Clinical Trials
The SERRA-I study, entering its early feasibility phase, is integral to exploring the initial use of the A-FLUX Reducer in patients manifesting symptomatic CMD. The research is supported by various clinical centers across the U.S. and the European Union. Notably, the first American patient was recruited at Yale-New Haven Hospital, under the co-leadership of Dr. Samit Shah, an interventional cardiologist known for his expertise in treating complex cardiovascular conditions.

Harry D. Rowland, PhD, CEO of VahatiCor, expressed excitement about this first enrollment, stating, "The treatment of our first American patient marks the entry of the A-FLUX Reducer System into clinical trials in the U.S. Currently, the cardiology field is shifting towards addressing microvascular illnesses like CMD as a primary care focus. The A-FLUX Reducer has been designed with this evolution in mind. I extend my gratitude to the researchers involved in the SERRA-I study and the patients who facilitate this important work."

Understanding CMD and Treatment Challenges
CMD significantly affects many people, and unlike traditional coronary artery disease, it does not present with visible arterial blockages, complicating diagnosis and treatment. Patients often endure chronic symptoms such as chest pain, yet lack effective treatment alternatives that address the unique aspects of CMD.

The A-FLUX Reducer System is designed to be catheter-placed within the coronary sinus, these devices work to influence the blood flow in the smaller cardiac vessels, ultimately treating the conditions associated with CMD. The first U.S. participant's recruitment marks a pivotal moment in generating crucial data and understanding the potential effectiveness of this therapeutic approach.

Looking to the Future
With VahatiCor's focus firmly on addressing the unmet medical needs posed by CMD, further developments within this clinical trial will be closely monitored by physicians and researchers alike. The company, housed in Santa Clara, California, remains at the forefront of evolving medical practices aimed at enhancing patient care in this challenging area of cardiology.

After achieving regulatory approvals, inclusive of the rigorous assessments set forth by American health authorities, VahatiCor hopes to expand its reach and improve the landscape of treatment for CMD not just in the U.S. but globally.

For continuous updates on VahatiCor's clinical progress and associated research, please navigate to their official website at vahaticor.com. It's important to note that the A-FLUX Reducer System is a investigational device and remains unapproved for commercial use by the U.S. FDA.